-
1.
公开(公告)号:WO2020161275A1
公开(公告)日:2020-08-13
申请号:PCT/EP2020/053069
申请日:2020-02-07
Applicant: MEDIBIOFARMA, S.L.
Inventor: PALOMINO LARIA, Julio Castro , CAMACHO GÓMEZ, Juan , RODRÍGUEZ IGLESIAS, Rodolfo , VELILLA MARTÍNEZ, Irene
IPC: C07D231/12 , C07D333/24 , C07C233/53 , C07D213/56 , C07D213/61 , A61P35/00 , A61K31/166 , A61K31/4409
Abstract: The present invention relates to novel, optionally substituted, N-benzyl-2- phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.
-
公开(公告)号:WO2019115498A1
公开(公告)日:2019-06-20
申请号:PCT/EP2018/084290
申请日:2018-12-11
Applicant: MEDIBIOFARMA, S.L.
IPC: C07D213/75 , C07C255/50 , C07D401/04 , C07D237/20 , C07C237/20 , C07D295/192 , A61P35/00 , A61K31/185 , A61K31/444 , A61K31/44 , A61K31/50
CPC classification number: C07D213/75 , A61P35/00 , C07C255/57 , C07D237/20 , C07D295/192 , C07D401/04
Abstract: The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.
-
3.
公开(公告)号:WO2019012172A1
公开(公告)日:2019-01-17
申请号:PCT/ES2018/070491
申请日:2018-07-09
Applicant: MEDIBIOFARMA, S.L.
IPC: C07D401/14 , C07D401/12 , C07D409/14 , A61K31/444 , A61K31/496 , A61P35/00
Abstract: La presente invención se refiere a nuevos derivados de heteroarilamida de fórmula (I) como inhibidores selectivos de la histona desacetilasa 1 y 2 (hdac1-2) a los procedimientos para su preparación, a composiciones farmacéuticas que comprenden dichos compuestos y al uso de dichos compuestos para fabricar un medicamento para el tratamiento de condiciones patológicas o enfermedades que pueden mejorar por inhibición la actividad de la histona desacetilasa clase I, particularmente HDAC1 y HDAC2, tales como cáncer, enfermedades neurodegenerativas, enfermedades infecciosas, enfermedades inflamatorias, insuficiencia cardíaca e hipertrofia cardíaca, diabetes, enfermedad renal poliquística, anemia de células falciformes y enfermedad de β -talasemia y a métodos para el tratamiento de las enfermedades antes mencionadas.
-
-